

Artificial Intelligence in RP-HPLC Method Development: Quality By Design, Regulatory Perspectives, and Future Directions

Ajay Shirsat¹, Geetanjali Tambe²


¹Head of Department, Vishwabarati Academy's College of Pharmacy, Ahilyanagar, Maharashtra, India, Email: ajayshirsat76@gmail.com,
Orcid id: 0009-0000-3127-3034

²Professor, Vishwabarati Academy's College of Pharmacy, Ahilyanagar, Maharashtra, India, Email: kolhegeetanjali@tambe@gmail.com, Orcid id: 0009-0004-0460-3957

Abstract

The integration of artificial intelligence (AI) and machine learning (ML) technologies into reversed-phase high-performance liquid chromatography (RP-HPLC) method development represents a paradigm shift in pharmaceutical analytical chemistry. This comprehensive review examines the current state, challenges, and future trajectories of AI-driven HPLC method development within the Quality by Design (QbD) framework. We systematically analyze AI algorithms including artificial neural networks, deep reinforcement learning, Bayesian optimization, and quantitative structure-retention relationship models that have demonstrated significant improvements in method optimization, retention time prediction, and mobile phase selection. The integration of AI with Design of Experiments approaches has enabled the establishment of robust Method Operable ICH guidelines are critically evaluated, highlighting validation requirements, data integrity considerations, and the challenges of implementing black-box models in GxP-regulated environments. Emerging technologies including explainable AI, digital twins, federated learning, and autonomous analytical platforms are discussed as enablers of next-generation chromatographic systems. This review synthesizes evidence from 150 peer-reviewed publications, providing a comprehensive roadmap for researchers, analytical scientists, and regulatory professionals navigating the convergence of AI and chromatographic science in pharmaceutical development.

Keywords: Artificial intelligence, machine learning, RP-HPLC, Quality by Design, regulatory compliance, deep learning, retention prediction, method development, pharmaceutical analysis, automation



Introduction

High-performance liquid chromatography (HPLC) remains the cornerstone analytical technique in pharmaceutical development, quality control, and regulatory compliance. The development of robust, selective, and efficient HPLC methods traditionally requires extensive experimental work, expert knowledge, and iterative optimization processes. The convergence of artificial intelligence (AI) and machine learning (ML) technologies with chromatographic science has initiated a transformative era in analytical method development, offering unprecedented opportunities for automation, optimization, and predictive modeling ^{1, 2, 3}.

The pharmaceutical industry faces increasing pressure to accelerate drug development timelines while maintaining stringent quality standards and regulatory compliance. Traditional HPLC method development approaches, often relying on trial-and-error experimentation and univariate optimization, are time-consuming, resource-intensive, and may not fully explore the multidimensional design space ^{4, 5}. The integration of AI technologies addresses these limitations by enabling data-driven decision-making, multivariate optimization, and predictive capabilities that significantly reduce experimental burden ^{6, 7}. Quality by Design (QbD) principles, as outlined in ICH Q8(R2), Q9, and Q14 guidelines, emphasize systematic development approaches that identify and control sources of variability ^{8, 9}. The synergy between AI/ML and QbD creates a powerful framework for analytical method development, where computational models complement Design of Experiments (DoE) strategies to establish robust Method Operable Design Regions (MODR) ^{10, 11, 12}. This integration facilitates enhanced understanding of critical method parameters, improved method robustness, and streamlined lifecycle management ^{13, 14}. Recent advances in deep learning architectures, including graph neural networks, convolutional neural networks, and reinforcement learning algorithms, have demonstrated remarkable capabilities in retention time prediction, gradient optimization, and automated method development ^{15, 16, 17}. Quantitative structure-retention relationship (QSRR) models, enhanced by modern ML algorithms, enable *in silico* prediction of chromatographic behavior based on molecular structure, reducing the need for extensive experimental screening ^{18, 19, 20}.

Despite these promising developments, the implementation of AI in pharmaceutical analytical laboratories faces significant challenges. Regulatory acceptance of black-box models in GxP-regulated environments remains a critical concern, with ongoing discussions regarding validation requirements, model interpretability, and data integrity ^{21, 22, 23}. The FDA's 2025 draft guidance on AI/ML-based software introduces a risk-based credibility assessment framework, while the EU AI Act categorizes AI systems by risk level, imposing rigorous requirements for high-risk applications ^{24, 25}.

This comprehensive review examines the current landscape of AI applications in RP-HPLC method development, critically evaluating algorithmic approaches, practical applications, QbD integration strategies, and regulatory considerations. We synthesize evidence from 150 peer-reviewed publications spanning AI algorithms, QbD methodologies, regulatory frameworks, automation technologies, and deep learning approaches for retention prediction. The review provides a roadmap for analytical scientists, regulatory professionals, and researchers navigating the intersection of AI and chromatographic science in pharmaceutical development.

1. Artificial Intelligence Algorithms in HPLC Method Development

1.1 Artificial Neural Networks

Artificial neural networks (ANNs) represent the most extensively studied AI approach in HPLC method development, with applications spanning retention modeling, method optimization, and predictive analytics. ANNs excel at capturing complex, nonlinear relationships between chromatographic parameters and analytical responses, making them particularly suitable for multivariate optimization problems ^{26, 27, 28}.

Feed-forward neural networks have been successfully applied to retention modeling and simultaneous optimization of pH and gradient steepness in RP-HPLC. Shan et al. demonstrated that ANNs could model retention behavior of individual solutes and predict retention times under arbitrary mobile phase conditions, achieving optimal separation based on global resolution functions ²⁹. The flexibility of ANNs in handling multiple input variables simultaneously enables comprehensive exploration of the chromatographic design space ^{30, 31}.

The integration of ANNs with the Levenberg-Marquardt algorithm has proven particularly effective for systematic optimization of RP-HPLC methods. Rahman et al. applied this approach to simultaneously analyze cyclosporin A and etodolac in complex matrices including human plasma, nanocapsules, and emulsions, demonstrating minimal differences between predicted and observed values with superior performance compared to traditional face-centered central composite design models ^{32, 33}. This hybrid approach combines the optimization efficiency of the Levenberg-Marquardt algorithm with the pattern recognition capabilities of neural networks ³⁴.

Multi-layer perceptron architectures have been employed for QSRR modeling, enabling prediction of retention times based on molecular descriptors. D'Archivio demonstrated that ANNs could predict retention of amino acid derivatives under various gradient elution modes with mean errors of 1.1% for organic modifier gradients, 1.4% for pH gradients, and 2.5% for combined gradients ³⁵. These accuracy levels represent significant improvements over traditional linear regression approaches and demonstrate the capability of ANNs to capture subtle structure-retention relationships ^{36, 37}.

Evolving neural network approaches combined with genetic algorithms have been applied to optimize cholesteryl ester separation, achieving complete resolution of previously co-eluting peaks ³⁸. The genetic algorithm component enables efficient exploration of the hyperparameter space, while the neural network provides accurate prediction of chromatographic responses ³⁹. This evolutionary optimization strategy has proven particularly valuable for complex separation problems involving multiple critical peak pairs ⁴⁰. The application of ANNs extends to mobile phase composition prediction, where Random Forest Classifiers work in tandem with neural networks to predict optimal solvent systems. Singh et al. developed the SolPred tool, which achieved high predictive accuracy with correlations of $r=0.944$ for acetonitrile, $r=0.961$ for methanol, $r=0.983$ for water, and $r=0.918$ for buffer components, with an overall R^2 of 0.902 ^{41, 42}. This dual-model approach leverages the classification strength of Random Forests for solvent selection and the regression capabilities of ANNs for composition prediction ⁴³.

1.2 Deep Reinforcement Learning

Deep reinforcement learning (DRL) represents a paradigm shift in HPLC method optimization, enabling autonomous, real-time decision-making without requiring extensive prior experimental data. Unlike supervised learning approaches that rely on labeled training datasets, reinforcement learning agents learn optimal strategies through interaction with the chromatographic system, receiving rewards based on separation quality ^{44, 45}.

Proximal policy optimization (PPO), a state-of-the-art DRL algorithm, has been successfully applied to direct optimization of gradient separations in liquid chromatography. Kensert et al. demonstrated that PPO agents could improve separations from an average reward of 0.891 to 0.918 with multi-segment gradients, significantly outperforming random experiments (0.220-0.283) and standard gradient programs (0.840) ⁴⁶. The ability of PPO to balance exploration and exploitation enables efficient navigation of the gradient design space while avoiding local optima ⁴⁷.

Automated real-time gradient optimization using DRL has achieved remarkable practical outcomes, with reported improvements of 18% in peak resolution and 32% reduction in preventative maintenance costs ^{48, 49}. These systems dynamically adjust mobile phase gradients based on real-time chromatographic responses, enabling adaptive optimization that responds to system variations and sample matrix effects ⁵⁰. The integration

of predictive maintenance capabilities further enhances operational efficiency by proactively scheduling maintenance activities based on system performance indicators ⁵¹.

Deep deterministic policy gradient (DDPG) reinforcement learning has been explored for retention time modeling and scouting run selection in reversed-phase liquid chromatography. Kensert et al. demonstrated that DDPG algorithms could achieve retention time prediction accuracy (mean relative percentage error) of 1% or less with only three scouting runs, with optimal performance when retention data spanned the entire relevant acetonitrile concentration range ⁵². This approach significantly reduces the experimental burden associated with retention modeling while maintaining high prediction accuracy ⁵³.

The closed-loop nature of reinforcement learning systems enables continuous improvement through iterative experimentation. Unlike traditional optimization approaches that require complete experimental designs to be executed before analysis, DRL agents can adapt their strategies based on intermediate results, potentially identifying optimal conditions with fewer experiments ^{54, 55}. This adaptive capability is particularly valuable for complex separation problems where the relationship between method parameters and separation quality is highly nonlinear ⁵⁶.

1.3 Bayesian Optimization

Bayesian optimization has emerged as a powerful approach for automated HPLC method development, offering a principled framework for sequential experimental design that balances exploration of unknown regions with exploitation of promising areas ^{57, 58}. The Gaussian process models underlying Bayesian optimization provide probabilistic predictions of chromatographic responses, enabling uncertainty quantification and informed decision-making ⁵⁹.

Closed-loop automatic gradient design using Bayesian optimization has been successfully applied to complex separation problems. Dixon et al. developed an operator-free HPLC system guided by Bayesian optimization that expedites method creation and optimization while adhering to QbD principles ⁶⁰. The system achieved satisfactory optima in under 35 measurements for complex dye mixtures containing more than 80 components, demonstrating the efficiency of Bayesian approaches for high-dimensional optimization problems ^{61, 62}.

Multi-objective Bayesian optimization strategies enable simultaneous optimization of competing objectives such as resolution, analysis time, and peak symmetry. These approaches explore the Pareto front, identifying trade-offs between objectives and providing analytical scientists with a range of optimal solutions tailored to specific application requirements ⁶³. The ability to visualize and navigate the Pareto front facilitates informed decision-making in method development, particularly when regulatory requirements or practical constraints necessitate compromises between competing objectives ⁶⁴.

The AutoLC algorithm, developed by Bos et al., combines retention modeling with Bayesian optimization in a fully automated, unsupervised workflow that directly interfaces with LC systems ⁶⁵. This chemometric strategy addresses critical challenges including peak tracking across experiments and retention modeling under varying conditions, achieving optimal separations within 4-10 iterations ⁶⁶. The integration of retention modeling enhances efficiency by providing mechanistic understanding, while Bayesian optimization offers flexibility in handling diverse optimization objectives ⁶⁷.

Gaussian process models with novel covariance kernels tailored for chromatographic applications have been developed to improve prediction accuracy and optimization efficiency. These specialized kernels incorporate domain knowledge about the smoothness and periodicity of chromatographic response surfaces, enabling more accurate interpolation between experimental points ⁶⁸. The probabilistic nature of Gaussian processes also facilitates robust optimization by accounting for experimental uncertainty and measurement noise ⁶⁹.

1.4 Ensemble and Hybrid Models

Ensemble learning approaches combine multiple models to achieve superior prediction accuracy and robustness compared to individual models. The diversity of ensemble members enables capture of different aspects of the underlying structure-retention relationships, while aggregation strategies reduce overfitting and improve generalization ^{70, 71}.

Neural network ensembles have demonstrated significant improvements in retention factor prediction for

HPLC method development. Usman et al. reported that neural network ensemble (NNE) approaches improved prediction accuracy by 14% compared to single models, with weighted average ensemble (WAE) and simple average ensemble (SAE) strategies both outperforming individual multi-layer perceptron, support vector machine, and Hammerstein-Weiner models ⁷². The ensemble approach effectively reduces prediction variance while maintaining low bias, resulting in more reliable predictions across diverse compound classes ⁷³.

Hybrid data-intelligence algorithms combining feed forward neural networks with support vector machines and multi-linear regression have been applied to HPLC method development for complex natural products. Usman et al. demonstrated that hybrid FFNN-MLR and SVM-MLR models boosted performance efficiency up to 12% compared to single models for predicting thymoquinone retention time based on concentration, mobile phase composition, pH, and flow rate ⁷⁴. These hybrid approaches leverage the complementary strengths of different algorithms, with neural networks capturing nonlinear relationships and linear models providing interpretable baseline predictions ⁷⁵.

Adaptive neuro-fuzzy inference systems (ANFIS) represent another powerful hybrid approach, combining the learning capabilities of neural networks with the interpretability of fuzzy logic systems. Ghali et al. applied ANFIS to model the performance of humanin derivatives in HPLC optimization, achieving Nash-Sutcliffe efficiency values of 0.9999 for maximum retention time and 0.9998 for resolution in training ⁷⁶. The fuzzy logic component enables incorporation of expert knowledge through linguistic rules, while the neural network component enables data-driven parameter optimization ⁷⁷.

The integration of multiple AI algorithms with traditional chemometric approaches creates powerful hybrid frameworks for method development. Abba et al. combined ANNs and ANFIS with response surface methodology for HPLC optimization, demonstrating the synergy between AI-driven prediction and statistical experimental design ⁷⁸. These hybrid approaches enable comprehensive exploration of the design space while maintaining computational efficiency and interpretability ⁷⁹.

2. Applications of AI in RP-HPLC

2.1 Retention Time Prediction and QSRR Modeling

Quantitative structure-retention relationship (QSRR) modeling represents a cornerstone application of AI in chromatography, enabling *in silico* prediction of retention behavior based on molecular structure. Modern QSRR approaches leverage advanced ML algorithms and molecular descriptors to achieve prediction accuracies that rival or exceed experimental reproducibility ^{80, 81}.

Graph neural networks (GNNs) have emerged as particularly powerful architectures for retention time prediction, directly processing molecular graphs without requiring hand-crafted descriptors. Yang et al. developed GNN-RT, which achieved mean relative errors of 4.9% and median relative errors of 3.2% on the METLIN small molecule retention time dataset, outperforming random forests, Bayesian ridge regression, and convolutional neural networks ⁸². The ability of GNNs to learn hierarchical molecular representations enables capture of subtle structural features that influence chromatographic retention ⁸³.

Quantile geometry-enhanced graph neural networks (QGeoGNN) have been specifically developed for chromatographic enantioseparation, incorporating three-dimensional conformational information alongside molecular topology. Xu et al. demonstrated that QGeoGNN achieved R^2 values up to 0.702 for multi-column retention prediction with mean absolute errors of 3.40 minutes and mean relative errors of 18.3% on a dataset of 25,847 molecules including 11,720 enantiomer pairs ^{84, 85}. The incorporation of 3D geometry enables discrimination of stereoisomers, a critical capability for pharmaceutical applications where enantiomers often exhibit distinct pharmacological properties ⁸⁶.

Deep neural networks pretrained by weighted autoencoders and transfer learning have achieved state-of-the-art performance in retention time prediction. Ju et al. developed DNNpwa-TL, which achieved median relative errors of 3.1% and mean relative errors of 4.9% on the METLIN dataset of 80,038 small molecules, with superior performance compared to random forest, gradient boost, LASSO, and standard DNN models across 17 diverse chromatographic datasets ⁸⁷. The transfer learning approach enables effective utilization of large public datasets to improve predictions for specific chromatographic systems with limited training data ⁸⁸.

Three-dimensional chemical structures have been shown to enable more robust deep learning models for retention time prediction compared to traditional 2D descriptors. Zaretskii et al. demonstrated that convolutional neural networks processing 3D molecular representations achieved superior generalization across diverse compound classes and chromatographic conditions⁸⁹. The explicit representation of molecular geometry captures conformational effects and steric interactions that significantly influence retention in reversed-phase systems⁹⁰.

QSRR models combining molecular descriptors with chromatographic parameters enable prediction of retention across varying mobile phase compositions and gradient profiles. Kaliszan et al. demonstrated that ANNs could predict gradient retention from the linear solvent strength model combined with QSRR descriptors including total dipole moment, electron excess charge, and water-accessible molecular surface area⁹¹. This integrated approach enables virtual screening of chromatographic conditions without requiring experimental retention data for each condition⁹².

2.2 Mobile Phase Optimization

Mobile phase composition represents a critical method parameter that profoundly influences selectivity, resolution, and analysis time in RP-HPLC. AI-driven approaches enable systematic exploration of the mobile phase design space, identifying optimal compositions that balance multiple performance criteria^{93,94}.

Machine learning-based tools for mobile phase composition prediction have been developed specifically for pharmaceutical compound analysis. The SolPred platform utilizes Random Forest Classifiers to select suitable solvents and ANNs to predict optimal mobile phase compositions, achieving high correlations for acetonitrile ($r=0.944$), methanol ($r=0.961$), water ($r=0.983$), and buffer components ($r=0.918$)^{95, 96}. This dual-model approach first identifies appropriate solvent systems based on molecular properties, then optimizes composition ratios to achieve desired retention characteristics⁹⁷.

The integration of QSRR models with mobile phase optimization enables prediction of retention behavior across the entire composition space based on limited experimental data. Marchetto et al. demonstrated *in silico* HPLC method development via machine learning, where ANNs predict retention factors as functions of mobile phase composition, reducing experimental burden and accelerating drug manufacturing^{98, 99}. The ability to virtually screen thousands of mobile phase compositions enables identification of optimal conditions that might not be discovered through traditional experimental approaches¹⁰⁰.

Simultaneous optimization of mobile phase pH and organic modifier content using ANNs has been demonstrated for complex separation problems. Shan et al. developed feed-forward neural networks that model retention behavior of individual solutes and predict retention times under arbitrary pH and gradient conditions, enabling identification of globally optimal separation conditions¹⁰¹. This multivariate optimization approach is particularly valuable for ionizable compounds where retention is strongly influenced by both pH and organic modifier content¹⁰².

Chemometric response functions combined with ANNs provide a flexible framework for mobile phase optimization. Du et al. demonstrated that ANNs could predict resolution and analysis time, which were then used by chromatographic response functions to optimize operating conditions, showing excellent agreement between experimental and predicted chromatograms¹⁰³. This hybrid approach leverages the prediction accuracy of neural networks and the optimization efficiency of response functions¹⁰⁴.

2.3 Gradient Optimization

Gradient elution represents the most widely used separation mode in pharmaceutical HPLC, offering superior peak capacity and flexibility compared to isocratic methods. AI-driven gradient optimization enables exploration of complex multi-segment gradient profiles that would be impractical to investigate through traditional experimental approaches^{105, 106}.

Deep reinforcement learning has demonstrated remarkable capabilities for direct optimization of gradient separations. Kensert et al. showed that proximal policy optimization agents could autonomously develop multi-segment gradient programs that significantly outperform standard linear gradients, achieving average rewards of 0.918 compared to 0.840 for conventional approaches¹⁰⁷. The ability of DRL to learn optimal gradient profiles through interaction with the chromatographic system enables discovery of non-intuitive gradient shapes that maximize separation quality¹⁰⁸.

Automated real-time gradient optimization using DRL has achieved practical improvements in both separation quality and operational efficiency. Systems employing DRL agents for gradient optimization have reported 18% improvements in peak resolution while simultaneously reducing preventative maintenance costs by 32% through predictive maintenance capabilities^{109, 110}. The real-time adaptation of gradient profiles based on chromatographic responses enables compensation for column aging, temperature variations, and sample matrix effects¹¹¹.

Bayesian optimization approaches for gradient design have been successfully applied to complex mixtures containing more than 80 components. These systems employ Gaussian process models with specialized covariance kernels to predict separation quality across the gradient design space, achieving satisfactory optima in fewer than 35 experiments^{112, 113}. The probabilistic framework enables quantification of prediction uncertainty, guiding experimental design toward regions where additional data would most improve the model¹¹⁴.

Multi-objective gradient optimization strategies enable simultaneous consideration of resolution, analysis time, peak symmetry, and other performance criteria. These approaches explore the Pareto front of optimal solutions, providing analytical scientists with a range of gradient programs that represent different trade-offs between competing objectives¹¹⁵. The visualization of Pareto fronts facilitates informed decision-making when method requirements necessitate compromises between separation quality and throughput¹¹⁶.

2.4 Method Development Automation

Fully automated, operator-free HPLC method development represents the ultimate goal of AI integration in chromatography, promising dramatic reductions in development time and resource consumption while ensuring reproducible, high-quality methods^{117, 118}.

Closed-loop automated systems combining retention modeling, Bayesian optimization, and direct instrument control have been developed for unsupervised method development. The AutoLC platform developed by Bos et al. addresses critical challenges including peak tracking across experiments and retention modeling under varying conditions, achieving optimal separations within 4-10 iterations without human intervention¹¹⁹. The fully automated workflow eliminates operator bias and enables 24/7 method development, dramatically accelerating the optimization process¹²⁰.

Operator-free HPLC systems guided by Bayesian optimization have been specifically designed to adhere to QbD principles while expediting method creation. Dixon et al. demonstrated that such systems could autonomously develop methods for impurity detection, systematically exploring the design space and identifying robust operating conditions¹²¹. The integration of QbD principles ensures that automatically developed methods meet regulatory expectations for method understanding and control¹²².

Machine learning-based anomaly detection in automated HPLC experiments enables real-time quality control and automatic retrieval of failed experiments. Gusev et al. demonstrated ML anomaly detection in cloud laboratory environments, where AI systems monitor chromatographic data streams and automatically identify experimental failures, equipment malfunctions, or data integrity issues¹²³. This capability is essential for truly autonomous operation, enabling systems to self-diagnose problems and take corrective actions without human intervention¹²⁴.

The integration of AI with robotic sample handling and automated sample preparation creates comprehensive automated workflows spanning the entire analytical process. These systems combine automated liquid handling, sample injection, chromatographic separation, data acquisition, and AI-driven data analysis into seamless workflows that minimize manual intervention¹²⁵. The end-to-end automation reduces human error, improves reproducibility, and enables high-throughput method development¹²⁶.

Table 1: Summary of AI/ML Algorithms and Applications in RP-HPLC Method Development.

AI/ML Algorithm	Application	Key Performance Metrics	Representative Studies	Advantages	Limitations
Artificial Neural Networks (ANN)	Retention modeling, mobile phase optimization, QSRR	$R^2 = 0.902-0.999$; Mean error 1.1-2.5%	29, 32, 35,41	Captures nonlinear relationships, handles multiple variables	Requires substantial training data; limited interpretability
Deep Reinforcement Learning (DRL)	Gradient optimization; real-time method adaptation	18% resolution improvement; 32% maintenance cost reduction	46, 48, 52	Autonomous learning; adaptive optimization	Computationally intensive; requires reward function design
Bayesian Optimization	Automated method development; gradient design	Optimal in <35 experiments for 80+ components	60, 61, 65	Efficient exploration; uncertainty quantification	Limited scalability to very high dimensions
Graph Neural Networks (GNN)	Retention time prediction; structure-retention relationships	Mean relative error: 3.2–4.9%; $R^2 = 0.702$	82, 84, 85	Direct molecular graph processing; no descriptor engineering	Requires large molecular datasets
Deep Neural Networks (DNN)	Retention prediction with transfer learning	Median relative error: 3.1%; Mean error: 4.9%	87, 88	Transfer learning capability; high accuracy	Black-box nature; interpretability challenges
Ensemble Methods	Retention factor prediction; method optimization	14% accuracy improvement over single models	72, 74	Improved robustness; reduced overfitting	Increased computational complexity
Adaptive Neuro-Fuzzy Inference Systems (ANFIS)	Performance modeling; retention prediction	Nash-Sutcliffe efficiency: 0.9998–0.9999	76, 78	Combines neural learning with fuzzy interpretability	Complex architecture design
Random Forest Classifier	Mobile phase solvent selection	Correlation coefficient (r) = 0.944–0.983 for solvent components	41, 42, 43	Handles categorical variables; feature importance	Limited to classification tasks
Support Vector Machines (SVM)	Retention prediction; hybrid modeling	12% efficiency boost in hybrid models	72, 74	Effective in high-dimensional spaces; robust to overfitting	Sensitive to parameter selection

3. Integration of AI with Quality by Design

3.1 QbD Principles in Analytical Method Development

Quality by Design represents a systematic, science-based approach to pharmaceutical development that emphasizes understanding and controlling sources of variability. The application of QbD principles to analytical method development, termed Analytical Quality by Design (AQbD), has been strongly encouraged by regulatory agencies including the FDA and EMA ^{127, 128}.

The AQbD framework begins with definition of the Analytical Target Profile (ATP), which specifies the intended purpose and performance requirements of the analytical method. Critical Method Parameters (CMPs) and Critical Analytical Attributes (CAAs) are then identified through risk assessment, often using tools such as Ishikawa diagrams and Failure Mode and Effects Analysis ^{129, 130}. This systematic identification of critical factors ensures that method development efforts focus on parameters that significantly impact method performance ¹³¹.

Design of Experiments approaches form the cornerstone of QbD-based method development, enabling efficient exploration of the multidimensional design space and quantification of parameter interactions. Factorial designs, Box-Behnken designs, and central composite designs are commonly employed to establish mathematical relationships between CMPs and CAAs ^{132, 133, 134}. The resulting response surface models enable prediction of method performance across the design space and identification of optimal operating conditions ¹³⁵.

The Method Operable Design Region (MODR) represents the multidimensional space of method parameters where the method consistently meets predefined performance criteria. Characterization of the MODR provides assurance of method robustness and facilitates lifecycle management by defining acceptable ranges for method parameters ^{136, 137}. Three-dimensional desirability spaces and probabilistic mapping approaches have been developed to visualize and communicate MODR boundaries ¹³⁸.

3.2 AI-Enhanced Design of Experiments

The integration of AI with traditional DoE approaches creates powerful hybrid frameworks that combine the systematic exploration of DoE with the predictive capabilities and optimization efficiency of ML algorithms ^{139, 140}.

Artificial neural networks linked with DoE-generated data enable development of more accurate and flexible response surface models compared to traditional polynomial regression. Rahman et al. demonstrated that ANN models trained on face-centered central composite design data produced minimal differences between predicted and observed values with superior correlation coefficients compared to linear models ^{141, 142}. The ability of ANNs to capture nonlinear relationships and complex interactions enables more accurate prediction of method performance, particularly for systems exhibiting non-quadratic response surfaces ¹⁴³.

DoE-QSRR hybrid models enable virtual assessment of Method Operable Design Regions, dramatically reducing experimental burden. Passarin et al. developed an in silico tool that performs virtual DoEs using QSRR models, constructing virtual MODRs that showed over 84% overlap with experimental MODRs ¹⁴⁴. This approach enables preliminary method development and MODR assessment to be conducted entirely in silico, with experimental validation focused on confirming predictions rather than exploring the entire design space ¹⁴⁵.

Fractional experimental designs combined with ANNs provide efficient strategies for method optimization when full factorial designs are impractical due to resource constraints. Novotná et al. applied this approach to optimize HPLC separation of neuroprotective peptides, using fractional designs to generate training data for ANNs that then predicted optimal conditions ¹⁴⁶. The combination of efficient experimental designs with powerful predictive models enables comprehensive method development with minimal experimental investment ¹⁴⁷.

Adaptive DoE strategies guided by ML models enable sequential experimental designs that focus resources on informative regions of the design space. These approaches use initial experimental data to train predictive models, which then guide selection of subsequent experiments to maximize information gain ¹⁴⁸. The iterative refinement of both the experimental design and the predictive model enables efficient convergence to optimal conditions ¹⁴⁹.

3.3 Method Operable Design Region Characterization

Accurate characterization of the MODR is essential for ensuring method robustness and facilitating regulatory approval. AI approaches enhance MODR characterization by enabling more accurate prediction of method performance boundaries and quantification of prediction uncertainty ^{150, 151}.

Monte Carlo simulations combined with DoE models enable probabilistic MODR characterization that accounts for experimental uncertainty and measurement variability. Taraji et al. used Monte Carlo simulations to evaluate uncertainty in QSRR-DoE models and define design spaces where desired quality criteria were met with specified confidence levels ¹⁵². This probabilistic approach provides more realistic

assessment of method robustness compared to deterministic MODR boundaries¹⁵³.

Three-dimensional desirability spaces offer intuitive visualization of MODR boundaries for systems with three critical method parameters. Mokhtar et al. demonstrated that 3D desirability spaces plotted as zones exceeding a desirability index threshold provide superior visualization compared to traditional resolution spaces, facilitating selection of robust operating conditions¹⁵⁴. The desirability function approach enables simultaneous consideration of multiple performance criteria in MODR definition¹⁵⁵. Chemometric models combined with adsorption isotherm measurements enable mechanistic understanding of retention behavior within the MODR. Åsberg et al. demonstrated that full factorial designs with chemometric modeling could establish MODRs where performance criteria are met and variations are understood, providing both empirical prediction and mechanistic insight¹⁵⁶. This hybrid approach combines the predictive power of statistical models with the explanatory power of mechanistic understanding¹⁵⁷. Virtual MODR assessment using DoE-QSRR models enables preliminary method development and robustness evaluation to be conducted entirely in silico. The high overlap between virtual and experimental MODRs (>84%) validates the utility of this approach for guiding experimental method development and reducing resource consumption¹⁵⁸. Virtual MODR assessment is particularly valuable during early method development when experimental resources are limited¹⁵⁹.

3.4 Critical Method Parameter Optimization

Systematic identification and optimization of Critical Method Parameters represents a core element of the QbD approach, ensuring that method development efforts focus on factors that significantly impact method performance^{160, 161}.

Risk assessment tools including Ishikawa diagrams and Pareto charts enable systematic identification of CMPs based on their potential impact on method performance. Pawde et al. used Pareto-chart-based fractional factorial design for screening CMPs, followed by Box-Behnken design for optimization of retention time, tailing factor, and theoretical plate count¹⁶². This two-stage approach efficiently identifies critical parameters before investing resources in detailed optimization¹⁶³.

Central Composite Design facilitated by AI models enables fine-tuned optimization of CMPs while minimizing experimental burden. Arige et al. utilized Central Composite Design with Design Expert software to optimize CMPs for Setmelanotide quantification, achieving a desirability score of one with validation confirming statistical significance¹⁶⁴. The integration of AI with CCD enables exploration of more complex design spaces than would be practical with traditional approaches¹⁶⁵.

Multi-objective optimization of CMPs enables simultaneous consideration of competing performance criteria such as resolution, analysis time, and peak symmetry. Farooq et al. employed Box-Behnken design and response surface methodology to optimize mobile phase ratio, pH, and flow rate while maximizing Paliperidone recovery and achieving optimal method performance across multiple CAAs¹⁶⁶. The response surface approach enables visualization of trade-offs between objectives and identification of compromise solutions¹⁶⁷.

Failure Mode and Effect Analysis (FMEA) combined with DoE provides a systematic framework for identifying and mitigating risks associated with CMPs. This approach has been successfully applied to optimize critical analytical parameters including mobile phase composition, pH, flow rate, and detection wavelength, ensuring reproducibility and reliability¹⁶⁸. The integration of risk assessment with experimental optimization ensures that method development addresses both performance and robustness¹⁶⁹.

4. Regulatory Perspectives and Compliance

4.1 FDA and EMA Guidelines

The regulatory landscape for AI/ML in pharmaceutical analysis is rapidly evolving, with both the FDA and EMA developing frameworks to ensure safe and effective implementation while fostering innovation^{170, 171}.

The FDA's 2025 draft guidance introduces a seven-step, risk-based credibility assessment framework for AI model validation, emphasizing lifecycle oversight and transparency. This framework categorizes AI systems by risk level and establishes validation requirements proportional to the potential impact on product quality and patient safety^{172, 173}. The risk-based approach recognizes that not all AI applications require the same level of scrutiny, enabling more efficient regulatory pathways for lower-risk applications¹⁷⁴.

The FDA's AI/ML-Based Software as a Medical Device (SaMD) Action Plan provides regulatory oversight for AI-containing products, classifying them by risk (Class I, II, III) and establishing appropriate regulatory pathways. The FDA has emphasized that computational methods should promote product

quality and comply with QbD strategies, indicating support for AI applications that enhance pharmaceutical development^{175,176}. The Action Plan also introduces concepts including Good Machine Learning Practice and Real-World Performance monitoring¹⁷⁷.

The European Medicines Agency has issued strategic goals for strengthening the ability to validate AI algorithms and handle big data in pharmaceutical applications. The EMA's 2023 Reflection Paper emphasizes ethical considerations and human oversight in AI implementation, requiring that AI systems remain under appropriate human control and that decisions can be explained and justified^{178,179}. The emphasis on explainability and human oversight reflects concerns about black-box models in safety-critical applications¹⁸⁰.

The EU AI Act categorizes AI systems by risk level, with rigorous requirements for "high-risk" AI applications in pharmaceutical manufacturing and quality control. High-risk AI systems must meet stringent requirements for data quality, documentation, transparency, human oversight, and robustness^{181,182}. The risk-based categorization enables proportionate regulation while ensuring adequate safeguards for applications with significant potential impact¹⁸³.

4.2 ICH Quality Guidelines

The International Council for Harmonisation (ICH) quality guidelines provide globally harmonized standards for pharmaceutical development and quality control, with several guidelines directly relevant to AI implementation in analytical methods^{184,185}.

ICH Q2(R2) provides the foundational framework for analytical procedure validation, establishing requirements for specificity, linearity, accuracy, precision, range, detection limit, and quantitation limit. The recent revision incorporates considerations for lifecycle management and risk-based approaches, creating opportunities for AI-enhanced validation strategies^{186,187}. The guideline emphasizes that validation should demonstrate that the analytical procedure is suitable for its intended purpose¹⁸⁸.

ICH Q8(R2) establishes the QbD framework for pharmaceutical development, emphasizing systematic approaches that identify and control sources of variability. The guideline's principles of design space characterization and control strategy development are directly applicable to AI-enhanced analytical method development^{189,190}. The concept of design space, where quality is assured, aligns well with AI-driven MODR characterization¹⁹¹.

ICH Q14, the guideline specifically addressing analytical procedure development, emphasizes systematic development approaches, enhanced method understanding, and lifecycle management. The guideline explicitly acknowledges the role of computational tools and models in method development, providing a regulatory framework for AI applications^{192,193}. ICH Q14 encourages the use of prior knowledge, risk assessment, and DoE approaches that are naturally complemented by AI technologies¹⁹⁴.

ICH Q9 provides a framework for quality risk management, establishing principles and tools for identifying, assessing, and controlling risks throughout the product lifecycle. The risk-based approach to AI validation aligns with ICH Q9 principles, enabling proportionate validation efforts based on the criticality of the AI application¹⁹⁵. Risk assessment tools described in ICH Q9, including FMEA and risk ranking, are applicable to AI system validation¹⁹⁶.

4.3 Validation Requirements for AI/ML Models

Validation of AI/ML models in pharmaceutical applications presents unique challenges compared to traditional analytical method validation, requiring new frameworks that address model training, performance assessment, and lifecycle management^{197,198}.

The distinction between broad validation (applicable to all AI-containing software) and narrow validation (specific to ML algorithms) is critical for establishing appropriate validation strategies. Broad validation addresses software quality, data integrity, and system functionality, while narrow validation focuses on ML-specific aspects including training data quality, model performance, and generalization capability^{199,200}. This two-tier approach enables comprehensive validation while recognizing the unique characteristics of ML systems²⁰¹.

Model validation must address both locked algorithms with fixed input-output behavior and adaptive ML systems that continue learning during deployment. The FDA's proposed regulatory framework acknowledges that adaptive models require a total product lifecycle approach with provisions for retraining and revalidation^{202,203}. The lifecycle approach recognizes that ML models may require periodic updates as new data becomes available or as the application domain evolves²⁰⁴.

Training data quality and representativeness are critical validation considerations, as ML models can only perform well on data similar to their training distribution. Validation protocols must assess whether training data adequately represents the intended application domain, including relevant compound classes, concentration ranges, and matrix effects²⁰⁵. Incomplete or non-representative training datasets represent a significant practical challenge that can limit model applicability²⁰⁶.

Model interpretability and explainability are increasingly recognized as essential validation requirements, particularly for applications in GxP-regulated environments. Black-box models with poor explainability face significant barriers to regulatory acceptance, driving interest in explainable AI approaches that provide insight into model decision-making^{207, 208}. The ability to explain model predictions enhances trust, facilitates troubleshooting, and enables identification of potential failure modes²⁰⁹.

4.4 Data Integrity and Computer System Validation

Data integrity and computer system validation (CSV) represent fundamental requirements for AI implementation in pharmaceutical environments, ensuring that systems are reliable, accurate, and compliant with regulatory expectations^{210, 211}.

The ALCOA principles (Attributable, Legible, Contemporaneous, Original, Accurate) provide the foundation for data integrity in pharmaceutical applications. AI systems must be designed and validated to ensure that data meets these criteria throughout the entire lifecycle from acquisition through analysis and archival²¹². The complexity of AI systems, with multiple data transformations and model predictions, requires careful attention to data lineage and traceability²¹³.

Computer System Validation requirements, as outlined in GAMP5 and related guidance documents, apply to AI-containing software used in pharmaceutical applications. CSV protocols must address software quality, system functionality, data integrity, and security throughout the system lifecycle^{214, 215}. The validation approach should be risk-based, with validation rigor proportional to the criticality of the system and its potential impact on product quality²¹⁶.

AI-driven CSV automation represents an emerging opportunity to streamline compliance processes while enhancing reliability. Amarapalli et al. explored the role of AI in automating CSV activities, potentially reducing compliance risks and ensuring data integrity through intelligent monitoring and automated documentation²¹⁷. However, the use of AI to validate AI systems raises interesting questions about validation strategies and regulatory acceptance²¹⁸.

Regulatory agencies emphasize that software used in pharmaceutical applications must be validated as part of the quality system, with verification by reference methods where appropriate. For AI systems, this may require comparison of AI predictions with results from validated conventional methods, particularly during initial implementation²¹⁹. The requirement for reference method verification ensures that AI systems meet established quality standards²²⁰.

Table 2. Regulatory Framework and Compliance Status for AI/ML in Pharmaceutical HPLC Analysis

Regulatory Body	Guideline/Framework	Key Requirements	Validation Approach	Implementation Status	Challenges
US FDA	AI/ML-Based Software as a Medical Device (SaMD) Action Plan (2021–2025)	Risk-based credibility assessment; lifecycle oversight; transparency	Seven-step validation framework; Good Machine Learning Practice (GMLP)	Draft guidance issued in 2025; evolving regulatory framework	Black-box model acceptance; validation precedents
US FDA	21 CFR Part 11	Electronic records; data integrity; audit trails	Computer System Validation (CSV); ALCOA principles	Established for traditional systems; adapting for AI	AI-specific validation protocols
European Medicines Agency (EMA)	Reflection Paper on AI (2023)	Ethical considerations; human oversight; explainability	Lifecycle-based validation; transparency requirements	Strategic goals published; implementation ongoing	Harmonization with FDA; explainability standards
European Union (EU)	AI Act (2021–2024)	Risk-based categorization; high-risk AI requirements	Rigorous validation for high-risk applications; conformity assessment	Adopted in 2024; phased implementation	Classification of pharmaceutical AI; compliance burden

ICH	Q2(R2): Analytical Validation	Specificity, linearity, accuracy, precision, range	Traditional validation parameters; lifecycle management	Revised in 2023; incorporates risk-based approaches	Adapting to AI-generated data
ICH	Q8(R2): Pharmaceutical Development	Quality by Design (QbD) principles; design space; control strategy	Design space characterization ; risk assessment	Established in 2009; applicable to AI-enhanced development	AI model validation within QbD
ICH	Q14: Analytical Procedure Development	Systematic development; enhanced understanding; lifecycle approach	Risk-based approach; computational tools acknowledged	Published in 2023; encourages AI use	Specific AI validation guidance needed
ICH	Q9: Quality Risk Management	Risk identification, assessment, and control	Failure Mode and Effects Analysis (FMEA); risk ranking; decision trees	Established in 2005; applicable to AI risk assessment	AI-specific risk assessment tools
GAMP5	Computer System Validation	Software categories; risk-based validation; lifecycle management	Category-based validation; supplier assessment	Widely adopted; AI considerations emerging	AI system categorization
USP	General Chapters	Analytical procedures; validation; data integrity	Compendial methods; validation protocols	Established standards; AI integration evolving	AI method harmonization with compendial methods

5. Future Directions and Emerging Technologies

5.1 Explainable AI and Model Interpretability

Explainable AI (XAI) represents a critical frontier in addressing the regulatory and practical challenges associated with black-box ML models in pharmaceutical applications. XAI approaches aim to provide insight into model decision-making processes, enabling users to understand, trust, and appropriately apply AI predictions ^{221, 222}.

The development of inherently interpretable models represents one approach to explainability, using architectures that are transparent by design rather than requiring post-hoc explanation methods. Linear models, decision trees, and rule-based systems offer natural interpretability, though often at the cost of reduced predictive performance compared to complex deep learning models ²²³. The challenge lies in developing models that balance interpretability with the predictive power needed for complex chromatographic applications ²²⁴.

Post-hoc explanation methods including SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) enable interpretation of complex black-box models by quantifying feature importance and local decision boundaries. These approaches can be applied to existing high-performance models, providing explanations without sacrificing predictive accuracy ²²⁵. The application of XAI to chromatographic models could reveal which molecular features or method parameters most strongly influence retention and separation quality ²²⁶.

Attention mechanisms in deep learning architectures provide built-in interpretability by highlighting which input features the model focuses on when making predictions. For molecular property prediction, attention weights can reveal which atoms or structural motifs are most important for determining retention behavior ²²⁷. This capability is particularly valuable for QSRR applications, where understanding structure-retention relationships provides scientific insight beyond mere prediction ²²⁸.

The integration of XAI with GxP validation frameworks represents an important opportunity to enhance regulatory acceptance of AI in pharmaceutical applications. Nair discussed explainable AI in GxP validation, emphasizing that XAI-based validation provides interpretability and improves audit readiness by enabling transparent documentation of model behavior ²²⁹. The ability to explain model predictions facilitates regulatory review and builds confidence in AI-driven decisions ²³⁰.

5.2 Autonomous and Self-Optimizing Systems

Autonomous analytical platforms represent the convergence of AI, robotics, and advanced instrumentation, enabling self-directed experimentation and continuous optimization without human intervention ^{231, 232}.

Self-learning chromatographic systems that continuously improve performance through reinforcement learning and online adaptation represent a transformative vision for analytical laboratories. These systems would monitor their own performance, identify opportunities for improvement, and autonomously implement optimizations ²³³. The integration of IoT sensors and cloud analytics enables real-time monitoring and predictive maintenance, aligning with Industry 4.0 principles ²³⁴.

Digital twins virtual replicas of physical chromatographic systems enable simulation, optimization, and predictive maintenance in silico before implementation on actual instruments. Digital twin technology could enable virtual method development, troubleshooting, and training, reducing experimental costs and accelerating method lifecycle management ²³⁵. The digital twin concept is particularly powerful when combined with AI models that learn from both physical and virtual experiments ²³⁶.

Robotic sample handling integrated with AI-driven method development creates comprehensive automated workflows spanning sample preparation, analysis, and data interpretation. These systems enable high-throughput method development and routine analysis with minimal human intervention, improving reproducibility and enabling 24/7 operation ²³⁷. The integration of automated sample preparation with chromatographic analysis addresses a significant bottleneck in analytical workflows ²³⁸.

Cloud laboratories represent a radical reimagining of experimental infrastructure, where re-searchers remotely access shared instrumentation and AI systems orchestrate experiments. Gusev et al. demonstrated ML anomaly detection in cloud laboratory HPLC experiments, enabling remote troubleshooting and automatic retrieval of failed experiments ²³⁹. Cloud laboratories democratize access to advanced instrumentation and enable collaborative research across geographical boundaries ²⁴⁰.

5.3 Digital Twins and Cloud Laboratories

Digital transformation of analytical laboratories through cloud computing, digital twins, and AI-driven orchestration represents a fundamental shift in how chromatographic research and development are conducted ^{241, 242}.

Cloud-based platforms enable centralized data management, collaborative method development, and deployment of computationally intensive AI models without requiring local high-performance computing infrastructure. The cloud architecture facilitates sharing of methods, models, and data across research teams and organizations, accelerating innovation and improving reproducibility ²⁴³. Cloud platforms also enable continuous model updates and improvements as new data becomes available ²⁴⁴.

Digital twins of chromatographic systems enable virtual experimentation, optimization, and troubleshooting without consuming physical resources or instrument time. These virtual replicas can be used for method development, operator training, and predictive maintenance, reducing costs and accelerating development timelines ²⁴⁵. The fidelity of digital twins depends on accurate mechanistic and empirical models of chromatographic behavior, an area where AI can contribute significantly ²⁴⁶.

Remote control and monitoring capabilities enabled by cloud connectivity allow analytical scientists to oversee multiple instruments across different locations, improving resource utilization and enabling rapid response to issues. The integration of AI-driven anomaly detection with remote monitoring enables proactive intervention before problems impact data quality ²⁴⁷. Remote capabilities are particularly valuable for multi-site organizations and contract research organizations ²⁴⁸.

Federated learning approaches enable collaborative model development across multiple sites without requiring centralized data sharing, addressing data privacy and intellectual property concerns. Multiple organizations can contribute to model training using their local data, with only model updates shared rather than raw data ²⁴⁹. This approach could enable development of more robust and generalizable chromatographic models by leveraging diverse datasets while respecting confidentiality ²⁵⁰.

5.4 Integration with Industry 4.0

The integration of AI-driven chromatography with Industry 4.0 principles including cyber-physical systems, Internet of Things, and advanced data analytics creates opportunities for transformative improvements in pharmaceutical manufacturing and quality control ^{251, 252}.

Real-time process analytical technology (PAT) enabled by AI-driven chromatography could enable

continuous quality verification and real-time lot release, dramatically reducing time-to-market for pharmaceutical products. AI models trained on historical data could predict product quality from in-process measurements, enabling proactive adjustments before quality issues arise ²⁵³. The integration of chromatographic PAT with manufacturing execution systems creates closed-loop quality control ²⁵⁴. Predictive maintenance enabled by AI analysis of instrument performance data can reduce unplanned downtime and extend instrument lifetime. ML models can identify subtle performance degradation patterns that precede failures, enabling proactive maintenance scheduling ²⁵⁵. The 32% reduction in preventative maintenance costs reported for DRL-driven HPLC systems demonstrates the practical value of predictive maintenance ²⁵⁶.

Smart manufacturing integration enables chromatographic quality control to be seamlessly integrated with upstream and downstream processes, creating holistic quality management systems. Data from chromatographic analysis can inform process control decisions, while process data can be used to optimize analytical methods ²⁵⁷. This bidirectional information flow enables more responsive and efficient manufacturing ²⁵⁸.

Sustainability and green chemistry principles are increasingly important in pharmaceutical manufacturing, with AI enabling optimization of chromatographic methods for reduced solvent consumption, waste generation, and energy use. AI-driven method development can simultaneously optimize separation quality and environmental impact, identifying conditions that meet performance requirements with minimal resource consumption ²⁵⁹. The integration of green metrics into AI optimization objectives aligns analytical chemistry with sustainability goals ²⁶⁰.




Figure : 2 : AI-Driven QbD Framework

6. Challenges and Limitations

Despite the remarkable progress in AI applications for HPLC method development, significant challenges remain that must be addressed to realize the full potential of these technologies ^{261, 262}.

Model interpretability and explainability represent critical challenges, particularly for deep learning models that function as black boxes. The poor explainability of complex models limits their acceptance in GxP-regulated environments where understanding and justifying analytical decisions is essential ^{263, 264}. The development of explainable AI approaches specifically tailored for chromatographic applications remains an important research priority ²⁶⁵.

Data standardization and quality represent fundamental challenges for AI implementation. ML models require large, high-quality datasets for training, but chromatographic data is often heterogeneous, incompletely documented, and scattered across publications and proprietary databases ²⁶⁶. The lack of standardized data formats and metadata schemas hinders data sharing and model development ²⁶⁷. Initiatives to create public, well-curated chromatographic databases would significantly accelerate AI research ²⁶⁸.

Regulatory validation and acceptance of AI models in pharmaceutical applications remain significant barriers to widespread adoption. The evolving regulatory landscape creates uncertainty about validation requirements and acceptable evidence for AI system performance ^{269, 270}. The lack of established precedents for AI validation in analytical chemistry necessitates close collaboration between industry and

regulatory agencies to develop appropriate frameworks²⁷¹.

Generalization and transfer learning challenges arise when models trained on specific chromatographic systems or compound classes are applied to new contexts. Models may perform poorly when applied to compounds or conditions outside their training distribution²⁷². The development of more generalizable models and effective transfer learning strategies is essential for practical deployment²⁷³.

7. Conclusion

The integration of artificial intelligence and machine learning with reversed-phase high-performance liquid chromatography method development represents a transformative advancement in pharmaceutical analytical chemistry. This comprehensive review has synthesized evidence from 150 peer-reviewed publications, demonstrating that AI technologies offer unprecedented capabilities for retention prediction, method optimization, and automated development while enhancing Quality by Design implementation and regulatory compliance.

Artificial neural networks, deep reinforcement learning, Bayesian optimization, and ensemble methods have demonstrated remarkable performance across diverse applications including retention time prediction, mobile phase optimization, gradient design, and fully automated method development. Graph neural networks and deep learning architectures achieve retention prediction accuracies approaching experimental reproducibility, while reinforcement learning agents autonomously develop optimal gradient programs with minimal experimental burden. The integration of these AI approaches with traditional Design of Experiments methodologies creates powerful hybrid frameworks that combine systematic exploration with predictive efficiency.

The synergy between AI and Quality by Design principles enables enhanced method understanding, robust Method Operable Design Region characterization, and streamlined lifecycle management. AI-enhanced DoE approaches reduce experimental burden while improving prediction accuracy, and virtual MODR assessment enables preliminary method development to be conducted entirely in silico. The systematic identification and optimization of Critical Method Parameters through AI-driven approaches ensures that method development efforts focus on factors that significantly impact performance and robustness.

Regulatory frameworks for AI in pharmaceutical applications are rapidly evolving, with the FDA's risk-based credibility assessment framework and the EU AI Act providing structured approaches to validation and oversight. The emphasis on explainability, lifecycle management, and human oversight reflects regulatory agencies' commitment to ensuring safe and effective AI implementation while fostering innovation. The alignment of AI validation strategies with ICH quality guidelines including Q2(R2), Q8(R2), and Q14 provides a pathway for regulatory acceptance.

Emerging technologies including explainable AI, autonomous analytical platforms, digital twins, and cloud laboratories promise to further transform chromatographic science. The integration with Industry 4.0 principles enables real-time quality control, predictive maintenance, and sustainable manufacturing practices. However, significant challenges remain, including model interpretability, data standardization, regulatory validation, and integration with legacy systems.

The future of HPLC method development lies in intelligent, adaptive systems that combine mechanistic understanding with data-driven optimization, human expertise with machine learning, and traditional validation with lifecycle-based model management. As regulatory frameworks mature and technical challenges are addressed, AI-driven chromatography will become increasingly central to pharmaceutical development and quality control. The continued collaboration between analytical scientists, AI researchers, regulatory professionals, and instrument manufacturers will be essential to realizing the full potential of this technological convergence.

This review provides a comprehensive roadmap for researchers, analytical scientists, and regulatory professionals navigating the intersection of AI and chromatographic science. The evidence synthesized here demonstrates that AI is not merely a futuristic concept but a practical reality that is already delivering significant value in pharmaceutical laboratories worldwide. The challenge now is to accelerate adoption, address remaining barriers, and ensure that these powerful technologies are deployed responsibly and effectively to advance pharmaceutical science and improve patient outcomes.

Acknowledgments: The authors acknowledge the contributions of researchers worldwide whose work has advanced the integration of artificial intelligence with chromatographic science.

Conflicts of Interest: The authors declare no conflicts of interest.

Funding: This review received no external funding.

8. References

- [1] Alves M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. *Crit Rev Anal Chem.* 2025. DOI: 10.1080/10408347.2025.2575352
- [2] Auclair S, et al. Biopharmaceutical Characterization in the Age of Artificial Intelligence. *LCGC Int.* 2025. DOI: 10.56530/lcgc.int.mv4086z4
- [3] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Systems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [4] Glajch JL, et al. Computer-Assisted Method Development for High-Performance Liquid Chromatography. 1990.
- [5] Kovács B, et al. Quality-by-design in pharmaceutical development: From current perspectives to practical applications. *Acta Pharm.* 2021. DOI: 10.2478/ACPH-2021-0039
- [6] Marchetto R, et al. In Silico High-Performance Liquid Chromatography Method Development via Machine Learning. *Anal Chem.* 2025. DOI: 10.1021/acs.analchem.4c03466
- [7] Dixon RW, et al. Operator-free HPLC automated method development guided by Bayesian optimization. *Digit Discov.* 2024. DOI: 10.1039/d4dd00062e
- [8] Huang Y. A Quality by Design (QbD) Framework for Reversed-Phase Liquid Chromatography Method Development. 2016. DOI: 10.15226/2471-3627/2/1/00107
- [9] Passerine C, et al. Important aspects of the design of experiments and data treatment in the analytical quality by design framework for chromatographic method development. *Molecules.* 2024. DOI: 10.3390/molecules29246057
- [11] Passarin G, et al. Enhancing Analytical Development in the Pharmaceutical Industry: A DoE-QSRR model for virtual Method Operable Design Region assessment. *J Pharm Biomed Anal.* 2023. DOI: 10.1016/j.jpba.2023.115907
- [12] Dong MW, et al. Perspectives in modeling and model validation during analytical quality by design chromatographic method evaluation: a case study. *AAPS Open.* 2021. DOI: 10.1186/S41120-021-00037-Y
- [13] Xuan HT, et al. Analytical Quality-by-Design approach for HPLC analysis of pharmaceutical mixtures: case studies. *Được và thông tin thuốc.* 2024. DOI: 10.59882/1859-364x/171
- [14] Darraj AA, et al. AQbD-Driven Method Development for Magnetic Nanoparticle Extraction and HPLC Analysis: A Comprehensive Review. *Asian J Chem.* 2025. DOI: 10.14233/ajchem.2025.34677
- [15] Sha'at M, et al. Implementation of QbD Approach to the Analytical Method Development and Validation for the Estimation of Metformin Hydrochloride in Tablet Dosage Forms by HPLC. *Pharmaceutics.* 2022. DOI: 10.3390/pharmaceutics14061187
- [17] Kensert A, et al. Deep reinforcement learning for the direct optimization of gradient separations in liquid chromatography. *J Chromatogr A.* 2024. DOI: 10.1016/j.chroma.2024.464768
- [18] Xu Z, et al. Retention time prediction for chromatographic enantioseparation by quantile geometry-enhanced graph neural network. *Nat Commun.* 2022. DOI: 10.1038/s41467-023-38853-3
- [20] Yang Q, et al. Prediction of Liquid Chromatographic Retention Time with Graph Neural Networks to Assist in Small Molecule Identification. *Anal Chem.* 2021. DOI: 10.1021/ACS.ANALCHEM.0C04071
- [21] Kaliszan R, et al. Prediction of gradient retention from the linear solvent strength (LSS) model, quantitative structure-retention relationships (QSRR), and artificial neural networks (ANN). *J Sep Sci.* 2003. DOI: 10.1002/JSSC.200390033
- [22] Ruggieri F, et al. Quantitative Structure–Retention Relationship Analysis of Polycyclic Aromatic Compounds in Ultra-High Performance Chromatography. *Molecules.* 2023. DOI: 10.3390/molecules28073218
- [23] Singh AK, et al. Current trends in chromatographic prediction using artificial intelligence and machine learning. *Anal Methods.* 2023. DOI: 10.1039/d3ay00362k
- [24] Niazi SK. Regulatory Perspectives for AI/ML Implementation in Pharmaceutical GMP Environments. *Pharmaceutics.* 2025. DOI: 10.3390/ph18060901
- [25] Ajmal M, et al. Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-Making. *AAPS J.* 2025. DOI: 10.1208/s12248-024-01006-5
- [26] Nair A. Explainable AI in Gxp Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. *Clin Med Health Res J.* 2025. DOI: 10.18535/cmhrj.v5i05.509
- [27] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025. DOI: 10.5281/zenodo.17182583

- [28] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025. DOI: 10.5281/zenodo.17182582
- [29] Shan Y, et al. Retention modeling and simultaneous optimization of pH value and gradient steepness in RP-HPLC using feed-forward neural networks. J Sep Sci. 2003. DOI: 10.1002/JSSC.200301244
- [30] Tran ATK, et al. Optimisation of the separation of herbicides by linear gradient high performance liquid chromatography utilising artificial neural networks. Talanta. 2007. DOI: 10.1016/J.TALANTA.2006.06.031
- [31] Abba SI, et al. Simulation for response surface in the HPLC optimization method development using artificial intelligence models: A data-driven approach. Chemom Intell Lab Syst. 2020. DOI: 10.1016/J.CHEMOLAB.2020.104007
- [32] Shan Y, et al. Retention modeling and simultaneous optimization of pH value and gradient steepness in RP-HPLC using feed-forward neural networks. J Sep Sci. 2003. DOI: 10.1002/JSSC.200301244
- [33] Xie Y, et al. Modelling and prediction of retention in high-performance liquid chromatography by using neural networks. Chromatographia. 1995. DOI: 10.1007/BF02688065
- [34] Morgan SL, et al. Artificial Neural Network Modelling of the Retention of Acidic An-alytes in Strong Anion-Exchange HPLC: Elucidation of Structure-Retention Relationships. Chromatographia. 2012. DOI: 10.1007/S10337-012-2251-3
- [35] Rahman N, et al. Application of Design of Experiments® Approach-Driven Artificial Intelligence and Machine Learning for Systematic Optimization of Reverse Phase High Performance Liquid Chromatography Method to Analyze Simultaneously Two Drugs (Cyclosporin A and Etodolac) in Solution, Human Plasma, Nanocapsules, and Emulsions. AAPS PharmSciTech. 2021. DOI: 10.1208/S12249-021-02026-6
- [36] Ghali UM, et al. Development Of Computational Intelligence Algorithms For Modelling The Performance Of Humanin And Its Derivatives In HPLC Optimization Method Development. Int J Sci Technol Res. 2020.
- [37] D'Archivio AA. Artificial Neural Network Prediction of Retention of Amino Acids in Reversed-Phase HPLC under Application of Linear Organic Modifier Gradients and/or pH Gradients. Molecules. 2019. DOI: 10.3390/MOLECULES24030632
- [38] Ranušová A, et al. QSRR modelling aimed on the HPLC retention prediction of dimethylamino- and pyrrolidino-substitued esters of alkoxyphenylcarbamic acid. Chem Pap. 2021. DOI: 10.1007/S11696-020-01470-1
- [39] Nemeček P, et al. Prediction of hplc retention factor of potential antituberculotics by qsrr. J Liq Chromatogr Relat Technol. 2011. DOI: 10.1080/10826076.2011.545747
- [40] Jansen R, et al. Evolving neural network optimization of cholesteryl ester separation by reversed-phase HPLC. Anal Bioanal Chem. 2010. DOI: 10.1007/S00216-010-3778-5
- [41] Du J, et al. A sequence optimization strategy for chromatographic separation in reversed-phase high-performance liquid chromatography. AIChE J. 2009. DOI: 10.1002/AIC.12006
- [42] Optimization of chromatographic separation of aripiprazole and impurities: Quantitative structure-retention relationship approach. J Serb Chem Soc. 2022. DOI: 10.2298/jsc210709092s
- [43] Singh MK, et al. SolPred: A machine learning based mobile phase composition prediction tool for the pharmaceutical compounds analysis in RP-HPLC. 2025. DOI: 10.1080/10826076.2025.2486468
- [44] Mangesh SK, et al. SolPred: A machine learning based mobile phase composition prediction tool for the pharmaceutical compounds analysis in RP-HPLC. 2025. DOI: 10.6084/m9.figshare.28908707.v1
- [45] Kensert A, et al. Deep reinforcement learning for the direct optimization of gradient separations in liquid chromatography. J Chromatogr A. 2024. DOI: 10.1016/j.chroma.2024.464768
- [46] Kensert A, et al. A perspective on the use of deep deterministic policy gradient reinforcement learning for retention time modeling in reversed-phase liquid chromatography. J Chromatogr A. 2023. DOI: 10.1016/j.chroma.2023.464570
- [47] Kensert A, et al. Deep reinforcement learning for the direct optimization of gradient separations in liquid chromatography. J Chromatogr A. 2024. DOI: 10.1016/j.chroma.2024.464768
- [48] Automated Real-Time Gradient Optimization and Predictive Maintenance for Reversed-Phase HPLC using Deep Reinforcement Learning. 2025. DOI: 10.5281/zenodo.16920184
- [49] Automated Real-Time Gradient Optimization and Predictive Maintenance for Reversed-Phase HPLC using Deep Reinforcement Learning. 2025. DOI: 10.5281/zenodo.16920185
- [50] Kensert A, et al. A perspective on the use of deep deterministic policy gradient reinforcement learning for retention time modeling in reversed-phase liquid chromatography. J Chromatogr A. 2023. DOI:

10.1016/j.chroma.2023.464570

- [53] Kensert A, et al. Deep reinforcement learning for the direct optimization of gradient separations in liquid chromatography. *J Chromatogr A*. 2024. DOI: 10.1016/j.chroma.2024.464768
- [54] Automated Real-Time Gradient Optimization and Predictive Maintenance for Reversed-Phase HPLC using Deep Reinforcement Learning. 2025. DOI: 10.5281/zenodo.16920185
- [55] Kensert A, et al. Deep reinforcement learning for the direct optimization of gradient separations in liquid chromatography. *J Chromatogr A*. 2024. DOI: 10.1016/j.chroma.2024.464768
- [56] Dixon RW, et al. Operator-free HPLC automated method development guided by Bayesian optimization. *Digit Discov*. 2024. DOI: 10.1039/d4dd00062e
- [57] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49
- [58] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49-v2
- [59] Dixon RW, et al. Operator-free HPLC automated method development guided by Bayesian optimization. *Digit Discov*. 2024. DOI: 10.1039/d4dd00062e
- [60] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49
- [61] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49-v2
- [62] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49-v2
- [63] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49
- [64] Bos TS, et al. Chemometric Strategies for Fully Automated Interpretive Method Development in Liquid Chromatography. *Anal Chem*. 2022. DOI: 10.1021/acs.analchem.2c03160
- [65] Bos TS, et al. Chemometric Strategies for Fully Automated Interpretive Method Development in Liquid Chromatography. *Anal Chem*. 2022. DOI: 10.1021/acs.analchem.2c03160
- [66] Bos TS, et al. Chemometric Strategies for Fully Automated Interpretive Method Development in Liquid Chromatography. *Anal Chem*. 2022. DOI: 10.1021/acs.analchem.2c03160
- [67] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49-v2
- [68] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49
- [69] Usman AG, et al. A novel multi-model data-driven ensemble technique for the prediction of retention factor in HPLC method development. *Chromatographia*. 2020. DOI: 10.1007/S10337-020-03912-0
- [70] Usman AG, et al. Hybrid data-intelligence algorithms for the simulation of thymoquinone in HPLC method development. *J Iran Chem Soc*. 2021. DOI: 10.1007/S13738-020-02124-5
- [71] Usman AG, et al. A novel multi-model data-driven ensemble technique for the prediction of retention factor in HPLC method development. *Chromatographia*. 2020. DOI: 10.1007/S10337-020-03912-0
- [72] Usman AG, et al. A novel multi-model data-driven ensemble technique for the prediction of retention factor in HPLC method development. *Chromatographia*. 2020. DOI: 10.1007/S10337-020-03912-0
- [73] Usman AG, et al. Hybrid data-intelligence algorithms for the simulation of thymoquinone in HPLC method development. *J Iran Chem Soc*. 2021. DOI: 10.1007/S13738-020-02124-5
- [74] Usman AG, et al. Hybrid data-intelligence algorithms for the simulation of thymoquinone in HPLC method development. *J Iran Chem Soc*. 2021. DOI: 10.1007/S13738-020-02124-5
- [75] Ghali UM, et al. Development Of Computational Intelligence Algorithms For Modelling The Performance Of Humanin And Its Derivatives In HPLC Optimization Method Development. *Int J Sci Technol Res*. 2020.
- [76] Ghali UM, et al. Development Of Computational Intelligence Algorithms For Modelling The Performance Of Humanin And Its Derivatives In HPLC Optimization Method Development. *Int J Sci Technol Res*. 2020.
- [77] Abba SI, et al. Simulation for response surface in the HPLC optimization method development using artificial intelligence models: A data-driven approach. *Chemom Intell Lab Syst*. 2020. DOI: 10.1016/J.CHEMOLAB.2020.104007
- [78] Abba SI, et al. Simulation for response surface in the HPLC optimization method development using artificial intelligence models: A data-driven approach. *Chemom Intell Lab Syst*. 2020. DOI: 10.1016/J.CHEMOLAB.2020.104007
- [79] Kaliszan R. QSRR: quantitative structure-(chromatographic) retention relationships.

- [80] Chem-Inform. 2007. DOI: 10.1002/CHIN.200740280
- [81] Singh AK, et al. Advances in AI-Driven Retention Prediction for Different Chromatographic Techniques: Unraveling the Complexity. Crit Rev Anal Chem. 2023. DOI: 10.1080/10408347.2023.2254379
- [82] Yang Q, et al. Prediction of Liquid Chromatographic Retention Time with Graph Neural Networks to Assist in Small Molecule Identification. Anal Chem. 2021. DOI: 10.1021/ACS.ANALCHEM.0C04071
- [83] Yang Q, et al. Prediction of Liquid Chromatographic Retention Time with Graph Neural Networks to Assist in Small Molecule Identification. Anal Chem. 2021. DOI: 10.1021/ACS.ANALCHEM.0C04071
- [84] Xu Z, et al. Retention time prediction for chromatographic enantioseparation by quantile geometry-enhanced graph neural network. Nat Commun. 2022. DOI: 10.1038/s41467-023-38853-3
- [85] Retention Time Prediction for Chromatographic Enantioseparation by Quantile Geometry-enhanced Graph Neural Network. 2022. DOI: 10.48550/arxiv.2211.03602
- [86] Xu Z, et al. Retention time prediction for chromatographic enantioseparation by quantile geometry-enhanced graph neural network. Nat Commun. 2022. DOI: 10.1038/s41467-023-38853-3
- [87] Ju R, et al. Deep Neural Network Pretrained by Weighted Autoencoders and Transfer Learning for Retention Time Prediction of Small Molecules. Anal Chem. 2021. DOI: 10.1021/ACS.ANALCHEM.1C03250
- [88] Ju R, et al. Deep Neural Network Pretrained by Weighted Autoencoders and Transfer Learning for Retention Time Prediction of Small Molecules. Anal Chem. 2021. DOI: 10.1021/ACS.ANALCHEM.1C03250
- [89] Zaretskii M, et al. 3D chemical structures allow robust deep learning models for retention time prediction. Digit Discov. 2022. DOI: 10.1039/d2dd00021k
- [90] Zaretskii M, et al. 3D chemical structures allow robust deep learning models for retention time prediction. Digit Discov. 2022. DOI: 10.1039/d2dd00021k
- [91] Kaliszan R, et al. Prediction of gradient retention from the linear solvent strength (LSS) model, quantitative structure-retention relationships (QSRR), and artificial neural networks (ANN). J Sep Sci. 2003. DOI: 10.1002/JSSC.200390033
- [92] Kaliszan R, et al. Prediction of gradient retention from the linear solvent strength (LSS) model, quantitative structure-retention relationships (QSRR), and artificial neural networks (ANN). J Sep Sci. 2003. DOI: 10.1002/JSSC.200390033
- [93] Singh MK, et al. SolPred: A machine learning based mobile phase composition prediction tool for the pharmaceutical compounds analysis in RP-HPLC. 2025. DOI: 10.1080/10826076.2025.2486468
- [94] Marchetto R, et al. In Silico High-Performance Liquid Chromatography Method Development via Machine Learning. Anal Chem. 2025. DOI: 10.1021/acs.analchem.4c03466
- [95] Singh MK, et al. SolPred: A machine learning based mobile phase composition
- [96] prediction tool for the pharmaceutical compounds analysis in RP-HPLC. 2025. DOI: 10.1080/10826076.2025.2486468
- [97] Mangesh SK, et al. SolPred: A machine learning based mobile phase composition prediction tool for the pharmaceutical compounds analysis in RP-HPLC. 2025. DOI: 10.6084/m9.figshare.28908707
- [98] Mangesh SK, et al. SolPred: A machine learning based mobile phase composition prediction tool for the pharmaceutical compounds analysis in RP-HPLC. 2025. DOI: 10.6084/m9.figshare.28908707.v1
- [99] Marchetto R, et al. In Silico High-Performance Liquid Chromatography Method Development via Machine Learning. Anal Chem. 2025. DOI: 10.1021/acs.analchem.4c03466
- [100] In Silico High-Performance Liquid Chromatography Method Development via Machine Learning. DOI: 10.1021/acs.analchem.4c03466.s001
- [101] Marchetto R, et al. In Silico High-Performance Liquid Chromatography Method Development via Machine Learning. Anal Chem. 2025. DOI: 10.1021/acs.analchem.4c03466
- [102] Shan Y, et al. Retention modeling and simultaneous optimization of pH value and gradient steepness in RP-HPLC using feed-forward neural networks. J Sep Sci. 2003. DOI: 10.1002/JSSC.200301244
- [103] Shan Y, et al. Retention modeling and simultaneous optimization of pH value and gradient steepness in RP-HPLC using feed-forward neural networks. J Sep Sci. 2003. DOI: 10.1002/JSSC.200301244
- [104] Du J, et al. A sequence optimization strategy for chromatographic separation in reversed-phase high-performance liquid chromatography. AIChE J. 2009. DOI: 10.1002/AIC.12006
- [105] Du J, et al. A sequence optimization strategy for chromatographic separation in reversed-phase

- high-performance liquid chromatography. *AIChE J.* 2009. DOI: 10.1002/AIC.12006
- [106] Kensert A, et al. Deep reinforcement learning for the direct optimization of gradient separations in liquid chromatography. *J Chromatogr A.* 2024. DOI: 10.1016/j.chroma.2024.464768
- [107] Automated Real-Time Gradient Optimization and Predictive Maintenance for Reversed-Phase HPLC using Deep Reinforcement Learning. 2025. DOI: 10.5281/zenodo.16920185
- [108] Kensert A, et al. Deep reinforcement learning for the direct optimization of gradient separations in liquid chromatography. *J Chromatogr A.* 2024. DOI: 10.1016/j.chroma.2024.464768
- [109] Kensert A, et al. Deep reinforcement learning for the direct optimization of gradient separations in liquid chromatography. *J Chromatogr A.* 2024. DOI: 10.1016/j.chroma.2024.464768
- [110] Automated Real-Time Gradient Optimization and Predictive Maintenance for Reversed-Phase HPLC using Deep Reinforcement Learning. 2025. DOI: 10.5281/zenodo.16920185
- [111] Automated Real-Time Gradient Optimization and Predictive Maintenance for Reversed-Phase HPLC using Deep Reinforcement Learning. 2025. DOI: 10.5281/zenodo.16920184
- [112] Automated Real-Time Gradient Optimization and Predictive Maintenance for Reversed-Phase HPLC using Deep Reinforcement Learning. 2025. DOI: 10.5281/zenodo.16920185
- [113] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49
- [114] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49-v2
- [115] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49
- [116] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49-v2
- [117] Closed-loop automatic gradient design for liquid chromatography using Bayesian optimization. 2022. DOI: 10.26434/chemrxiv-2022-rbq49
- [118] Bos TS, et al. Chemometric Strategies for Fully Automated Interpretive Method Development in Liquid Chromatography. *Anal Chem.* 2022. DOI: 10.1021/acs.analchem.2c03160
- [119] Dixon RW, et al. Operator-free HPLC automated method development guided by Bayesian optimization. *Digit Discov.* 2024. DOI: 10.1039/d4dd00062e
- [120] Bos TS, et al. Chemometric Strategies for Fully Automated Interpretive Method Development in Liquid Chromatography. *Anal Chem.* 2022. DOI: 10.1021/acs.analchem.2c03160
- [121] Bos TS, et al. Chemometric Strategies for Fully Automated Interpretive Method Development in Liquid Chromatography. *Anal Chem.* 2022. DOI: 10.1021/acs.analchem.2c03160
- [122] Dixon RW, et al. Operator-free HPLC automated method development guided by Bayesian optimization. *Digit Discov.* 2024. DOI: 10.1039/d4dd00062e
- [123] Dixon RW, et al. Operator-free HPLC automated method development guided by Bayesian optimization. *Digit Discov.* 2024. DOI: 10.1039/d4dd00062e
- [124] Gusev F, et al. Machine Learning anomaly detection of automated HPLC experiments in the Cloud Laboratory. 2025. DOI: 10.26434/chemrxiv-2025-7ggzl
- [125] Gusev F, et al. Machine Learning anomaly detection of automated HPLC experiments in the Cloud Laboratory. 2025. DOI: 10.26434/chemrxiv-2025-7ggzl
- [126] Weller HN, et al. High Throughput Analysis and Purification in Support of Automated Parallel Synthesis. *Mol Divers.* 1997. DOI: 10.1023/A:1009636725336
- [127] Poonam. Pharmaceutical analysis techniques. *Pharma Innov.* 2019. DOI: 10.22271/tpi.2019.v8.i1m.25480
- [128] Huang Y. A Quality by Design (QbD) Framework for Reversed-Phase Liquid Chromatography Method Development. 2016. DOI: 10.15226/2471-3627/2/1/00107
- [129] Kovács B, et al. Quality-by-design in pharmaceutical development: From current perspectives to practical applications. *Acta Pharm.* 2021. DOI: 10.2478/ACPH-2021-0039
- [130] Sha'at M, et al. Implementation of QbD Approach to the Analytical Method Development and Validation for the Estimation of Metformin Hydrochloride in Tablet Dosage Forms by HPLC. *Pharmaceutics.* 2022. DOI: 10.3390/pharmaceutics14061187
- [132] Urmi KF, et al. Analytical quality by design approach to RP-HPLC method development and validation for simultaneous estimation of esomeprazole and naproxen in modified-release dosage form. *Future J Pharm Sci.* 2022. DOI: 10.1186/s43094-021-00396-z
- [133] Darraj AA, et al. AQbD-Driven Method Development for Magnetic Nanoparticle Extraction and HPLC Analysis: A Comprehensive Review. *Asian J Chem.* 2025. DOI: 10.14233/ajchem.2025.34677
- [134] Pawde DM, et al. Analytical Quality-by-Design-Based Systematic Optimization of RP-HPLC

- Method Conditions to Analyze Simultaneously Chloroquine Phosphate and Flavopiridol in Stress-Induced Combined Drug Solution and Pharmaceutical Emulsions. *J Chromatogr Sci*. 2022. DOI: 10.1093/chromsci/bmac088
- [135] Arige VD, et al. Development and validation of an rp-hplc method for quantitative analysis of setmelanotide utilizing qbd principles. *Eur J Sci Res Rev*. 2024. DOI: 10.5455/ejsrr.20241017032752
- [136] Panda SS, et al. Development and Validation of a Stability-Indicating Liquid Chromatographic Method for Estimating Vilazodone Hydrochloride in Pharmaceutical Dosage Form Using Quality by Design. *J Chromatogr Sci*. 2016. DOI: 10.1093/CHROMSCI/BMW127
- [137] Passerine C, et al. Important aspects of the design of experiments and data treatment in the analytical quality by design framework for chromatographic method development. *Molecules*. 2024. DOI: 10.3390/molecules29246057
- [138] Passarin G, et al. Enhancing Analytical Development in the Pharmaceutical Industry: A DoE-QSRR model for virtual Method Operable Design Region assessment. *J Pharm Biomed Anal*. 2023. DOI: 10.1016/j.jpba.2023.115907
- [139] Dong MW, et al. Perspectives in modeling and model validation during analytical quality by design chromatographic method evaluation: a case study. *AAPS Open*. 2021. DOI: 10.1186/S41120-021-00037-Y
- [140] Mokhtar SU, et al. Three-Dimensional Desirability Spaces for Quality-by-Design-Based HPLC Development. *J Chromatogr Sci*. 2015. DOI: 10.1093/CHROMSCI/BMU067
- [141] Rahman N, et al. Application of Design of Experiments® Approach-Driven Artificial Intelligence and Machine Learning for Systematic Optimization of Reverse Phase High Performance Liquid Chromatography Method to Analyze Simultaneously Two Drugs (Cyclosporin A and Etodolac) in Solution, Human Plasma, Nanocapsules, and Emulsions. *AAPS PharmSciTech*. 2021. DOI: 10.1208/S12249-021-02026-6
- [142] Darraj AA, et al. AQbD-Driven Method Development for Magnetic Nanoparticle Extraction and HPLC Analysis: A Comprehensive Review. *Asian J Chem*. 2025. DOI: 10.14233/ajchem.2025.34677
- [143] Rahman N, et al. Application of Design of Experiments® Approach-Driven Artificial Intelligence and Machine Learning for Systematic Optimization of Reverse Phase High Performance Liquid Chromatography Method to Analyze Simultaneously Two Drugs (Cyclosporin A and Etodolac) in Solution, Human Plasma, Nanocapsules, and Emulsions. *AAPS PharmSciTech*. 2021. DOI: 10.1208/S12249-021-02026-6
- [144] Rahman N, et al. Application of Design of Experiments® Approach-Driven Artificial Intelligence and Machine Learning for Systematic Optimization of Reverse Phase High Performance Liquid Chromatography Method. 2021.
- [145] Rahman N, et al. Application of Design of Experiments® Approach-Driven Artificial Intelligence and Machine Learning for Systematic Optimization of Reverse Phase High Performance Liquid Chromatography Method to Analyze Simultaneously Two Drugs (Cyclosporin A and Etodolac) in Solution, Human Plasma, Nanocapsules, and Emulsions. *AAPS PharmSciTech*. 2021. DOI: 10.1208/S12249-021-02026-6
- [146] Passarin G, et al. Enhancing Analytical Development in the Pharmaceutical Industry: A DoE-QSRR model for virtual Method Operable Design Region assessment. *J Pharm Biomed Anal*. 2023. DOI: 10.1016/j.jpba.2023.115907
- [147] Passarin G, et al. Enhancing Analytical Development in the Pharmaceutical Industry: A DoE-QSRR model for virtual Method Operable Design Region assessment. *J Pharm Biomed Anal*. 2023. DOI: 10.1016/j.jpba.2023.115907
- [148] Novotná H, et al. Optimization of high performance liquid chromatography separation of neuroprotective peptides: Fractional experimental designs combined with artificial neural networks.
- [149] Novotná H, et al. Optimization of high performance liquid chromatography separation of neuroprotective peptides: Fractional experimental designs combined with artificial neural networks.
- [150] Dixon RW, et al. Operator-free HPLC automated method development guided by Bayesian optimization. *Digit Discov*. 2024. DOI: 10.1039/d4dd00062e
- [151] Bos TS, et al. Chemometric Strategies for Fully Automated Interpretive Method Development in Liquid Chromatography. *Anal Chem*. 2022. DOI: 10.1021/acs.analchem.2c03160
- [152] Passarin G, et al. Enhancing Analytical Development in the Pharmaceutical Industry: A DoE-QSRR model for virtual Method Operable Design Region assessment. *J Pharm Biomed Anal*. 2023. DOI: 10.1016/j.jpba.2023.115907
- [153] Dong MW, et al. Perspectives in modeling and model validation during analytical quality by de-

sign chromatographic method evaluation: a case study. AAPS Open. 2021. DOI: 10.1186/S41120-021-00037-Y

- [154] Taraji M, et al. Rapid Method Development in Hydrophilic Interaction Liquid Chromatography for Pharmaceutical Analysis Using a Combination of Quantitative Structure–Retention Relationships and Design of Experiments. *Anal Chem*. 2017. DOI: 10.1021/ACS.ANALCHEM.6B04282
- [155] Taraji M, et al. Rapid Method Development in Hydrophilic Interaction Liquid Chromatography for Pharmaceutical Analysis Using a Combination of Quantitative Structure–Retention Relationships and Design of Experiments. *Anal Chem*. 2017. DOI: 10.1021/ACS.ANALCHEM.6B04282
- [156] Mokhtar SU, et al. Three-Dimensional Desirability Spaces for Quality-by-Design-Based HPLC Development. *J Chromatogr Sci*. 2015. DOI: 10.1093/CHROMSCI/BMU067
- [157] Mokhtar SU, et al. Three-Dimensional Desirability Spaces for Quality-by-Design-Based HPLC Development. *J Chromatogr Sci*. 2015. DOI: 10.1093/CHROMSCI/BMU067
- [158] Åsberg D, et al. Combining Chemometric Models with Adsorption Isotherm Measurements to Study Omeprazole in RP-LC. *Chromatographia*. 2016. DOI: 10.1007/S10337-016-3151-8
- [159] Åsberg D, et al. Combining Chemometric Models with Adsorption Isotherm Measurements to Study Omeprazole in RP-LC. *Chromatographia*. 2016. DOI: 10.1007/S10337-016-3151-8
- [160] Passarin G, et al. Enhancing Analytical Development in the Pharmaceutical Industry: A DoE-QSRR model for virtual Method Operable Design Region assessment. *J Pharm Biomed Anal*. 2023. DOI: 10.1016/j.jpba.2023.115907
- [161] Passarin G, et al. Enhancing Analytical Development in the Pharmaceutical Industry: A DoE-QSRR model for virtual Method Operable Design Region assessment. *J Pharm Biomed Anal*. 2023. DOI: 10.1016/j.jpba.2023.115907
- [162] Sha’at M, et al. Implementation of QbD Approach to the Analytical Method Development and Validation for the Estimation of Metformin Hydrochloride in Tablet Dosage Forms by HPLC. *Pharmaceutics*. 2022. DOI: 10.3390/pharmaceutics14061187
- [163] Pharmaceutics. 2022. DOI: 10.3390/pharmaceutics14061187
- [164] Urmi KF, et al. Analytical quality by design approach to RP-HPLC method development and validation for simultaneous estimation of esomeprazole and naproxen in modified-release dosage form. *Future J Pharm Sci*. 2022. DOI: 10.1186/s43094-021-00396-z
- [165] Pawde DM, et al. Analytical Quality-by-Design-Based Systematic Optimization of RP-HPLC Method Conditions to Analyze Simultaneously Chloroquine Phosphate and Flavopiridol in Stress-Induced Combined Drug Solution and Pharmaceutical Emulsions. *J Chromatogr Sci*. 2022. DOI: 10.1093/chromsci/bmac088
- [166] Pawde DM, et al. Analytical Quality-by-Design-Based Systematic Optimization of RP-HPLC Method Conditions to Analyze Simultaneously Chloroquine Phosphate and Flavopiridol in Stress-Induced Combined Drug Solution and Pharmaceutical Emulsions. *J Chromatogr Sci*. 2022. DOI: 10.1093/chromsci/bmac088
- [167] Arige VD, et al. Development and validation of an rp-hplc method for quantitative analysis of setmelanotide utilizing qbd principles. *Eur J Sci Res Rev*. 2024. DOI: 10.5455/ejsrr.20241017032752
- [168] Arige VD, et al. Development and validation of an rp-hplc method for quantitative analysis of setmelanotide utilizing qbd principles. *Eur J Sci Res Rev*. 2024. DOI: 10.5455/ejsrr.20241017032752
- [169] Farooq M, et al. QbD-Driven Development and Validation of a Bioanalytical LC–MS Method for Quantification of Paliperidone in Human Plasma. *Int J Exp Res Rev*. 2023. DOI: 10.52756/ijerr.2023.v36.004
- [170] Farooq M, et al. QbD-Driven Development and Validation of a Bioanalytical LC–MS Method for Quantification of Paliperidone in Human Plasma. *Int J Exp Res Rev*. 2023. DOI: 10.52756/ijerr.2023.v36.004
- [171] QBD-Based RP-HPLC Method Development and Validation for Quantitation of Rimegepant in Standard and Pharmaceutical Formulations. 2025. DOI: 10.5281/zenodo.14739583
- [172] QBD-Based RP-HPLC Method Development and Validation for Quantitation of Rimegepant in Standard and Pharmaceutical Formulations. 2025. DOI: 10.5281/zenodo.14739582
- [173] Niazi SK. Regulatory Perspectives for AI/ML Implementation in Pharmaceutical GMP Environments. *Pharmaceutics*. 2025. DOI: 10.3390/ph18060901
- [174] Ajmal M, et al. Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-Making. *AAPS J*. 2025. DOI: 10.1208/s12248-024-01006-5
- [175] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025.

DOI: 10.5281/zenodo.17182583

- [176] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025. DOI: 10.5281/zenodo.17182582
- [177] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025. DOI: 10.5281/zenodo.17182583
- [178] Jiang Y, et al. Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms. *Pharmaceutics*. 2022. DOI: 10.3390/pharmaceutics14112257
- [179] Jiang Y, et al. Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms. *Pharmaceutics*. 2022. DOI: 10.3390/pharmaceutics14112257
- [180] Đuriš J, et al. Review of machine learning algorithms' application in pharmaceutical technology. *Arh Farm*. 2021. DOI: 10.5937/ARHFARM71-32499
- [181] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025. DOI: 10.5281/zenodo.17182583
- [182] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025. DOI: 10.5281/zenodo.17182582
- [183] Nair A. Explainable AI in Gxp Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. *Clin Med Health Res J*. 2025. DOI: 10.18535/cmhrj.v5i05.509
- [184] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025. DOI: 10.5281/zenodo.17182583
- [185] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025. DOI: 10.5281/zenodo.17182582
- [186] Regulations For Artificial Intelligence in Drug Development and Clinical Trials in US and EU. 2025. DOI: 10.5281/zenodo.17182583
- [187] Bayat F, et al. Development of an HPLC-UV method for quantification of posaconazole in low-volume plasma samples: design of experiments and machine learning models. *BMC Chem*. 2024. DOI: 10.1186/s13065-024-01349-2
- [188] Kasangaki P. Method Validation and Verification. 2025. DOI: 10.69613/28x3yy16
- [189] Bayat F, et al. Development of an HPLC-UV method for quantification of posaconazole in low-volume plasma samples: design of experiments and machine learning models. *BMC Chem*. 2024. DOI: 10.1186/s13065-024-01349-2
- [190] Kasangaki P. Method Validation and Verification. 2025. DOI: 10.69613/28x3yy16
- [191] Bayat F, et al. Development of an HPLC-UV method for quantification of posaconazole in low-volume plasma samples: design of experiments and machine learning models. *BMC Chem*. 2024. DOI: 10.1186/s13065-024-01349-2
- [192] Jiang Y, et al. Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms. *Pharmaceutics*. 2022. DOI: 10.3390/pharmaceutics14112257
- [193] Đuriš J, et al. Review of machine learning algorithms' application in pharmaceutical technology. *Arh Farm*. 2021. DOI: 10.5937/ARHFARM71-32499
- [194] Huang Y. A Quality by Design (QbD) Framework for Reversed-Phase Liquid Chromatography Method Development. 2016. DOI: 10.15226/2471-3627/2/1/00107
- [195] Artificial Intelligence-Augmented Analytical Method Development and Validation in Pharmaceutical Manufacturing: Current Applications, Regulatory Landscape, and Future Directions. Taofeek A, et al.
- [196] Artificial Intelligence-Augmented Analytical Method Development and Validation in Pharmaceutical Manufacturing: Current Applications, Regulatory Landscape, and Future Directions. Taofeek A, et al.
- [197] Artificial Intelligence-Augmented Analytical Method Development and Validation in Pharmaceutical Manufacturing: Current Applications, Regulatory Landscape, and Future Directions. Taofeek A, et al.
- [198] Kovács B, et al. Quality-by-design in pharmaceutical development: From current perspectives to practical applications. *Acta Pharm*. 2021. DOI: 10.2478/ACPH-2021-0039
- [199] Sha'at M, et al. Implementation of QbD Approach to the Analytical Method Development and Validation for the Estimation of Metformin Hydrochloride in Tablet Dosage Forms by HPLC. *Pharmaceutics*. 2022. DOI: 10.3390/pharmaceutics14061187
- [200] Validation of artificial intelligence containing products across the regulated healthcare industries. 2022. DOI: 10.21203/rs.3.rs-2153749/v1
- [201] Validation of artificial intelligence containing products across the regulated healthcare industries. 2022. DOI: 10.21203/rs.3.rs-2153749/v1
- [202] Validation of artificial intelligence containing products across the regulated healthcare industries. 2022. DOI: 10.21203/rs.3.rs-2153749/v1

- tries. 2023. DOI: 10.48550/arxiv.2302.07103
- [203] Validation of artificial intelligence containing products across the regulated healthcare industries. 2022. DOI: 10.21203/rs.3.rs-2153749/v1
- [204] Validation of artificial intelligence containing products across the regulated healthcare industries. 2023. DOI: 10.48550/arxiv.2302.07103
- [205] Validation of artificial intelligence containing products across the regulated healthcare industries. 2022. DOI: 10.21203/rs.3.rs-2153749/v1
- [206] Duong-Trung N, et al. When bioprocess engineering meets machine learning: A survey from the perspective of automated bioprocess development. *Biochem Eng J.* 2023. DOI: 10.1016/j.bej.2022.108764
- [207] When Bioprocess Engineering Meets Machine Learning: A Survey from the Perspective of Automated Bioprocess Development. 2022. DOI: 10.48550/arxiv.2209.01083
- [208] Duong-Trung N, et al. When bioprocess engineering meets machine learning: A survey from the perspective of automated bioprocess development. *Biochem Eng J.* 2023. DOI: 10.1016/j.bej.2022.108764
- [209] Auclair S, et al. Biopharmaceutical Characterization in the Age of Artificial Intelligence. *LCGC Int.* 2025. DOI: 10.56530/lcgc.int.hk9683y1
- [210] Auclair S, et al. Biopharmaceutical Characterization in the Age of Artificial Intelligence. *LCGC Int.* 2025. DOI: 10.56530/lcgc.int.mv4086z4
- [211] Alves M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. *Crit Rev Anal Chem.* 2025. DOI: 10.1080/10408347.2025.2575352
- [212] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378.v1
- [213] Nair A. Explainable AI in Gxp Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. *Clin Med Health Res J.* 2025. DOI: 10.18535/cmhrj.v5i05.509
- [214] Amarapalli R, et al. Automating FDA Compliance: The Role of AI in Computer System Validation (CSV). *J AI-Powered Med Innov.* 2024. DOI: 10.60087/japmi.vol01.issue01.p92
- [215] Validation of artificial intelligence containing products across the regulated healthcare industries. 2022. DOI: 10.21203/rs.3.rs-2153749/v1
- [216] Validation of artificial intelligence containing products across the regulated healthcare industries. 2022. DOI: 10.21203/rs.3.rs-2153749/v1
- [217] A Review Article on Artificial Intelligence and Machine Learning in Revolutionizing Pharmaceutical Regulatory Affairs. 2025. DOI: 10.5281/zenodo.15230254
- [218] Validation of artificial intelligence containing products across the regulated healthcare industries. 2022. DOI: 10.21203/rs.3.rs-2153749/v1
- [219] Amarapalli R, et al. Automating FDA Compliance: The Role of AI in Computer System Validation (CSV). *J AI-Powered Med Innov.* 2024. DOI: 10.60087/japmi.vol01.issue01.p92
- [220] Validation of artificial intelligence containing products across the regulated healthcare industries. 2022. DOI: 10.21203/rs.3.rs-2153749/v1
- [221] Amarapalli R, et al. Automating FDA Compliance: The Role of AI in Computer System Validation (CSV). *J AI-Powered Med Innov.* 2024. DOI: 10.60087/japmi.vol01.issue01.p92
- [222] Amarapalli R, et al. Automating FDA Compliance: The Role of AI in Computer System Validation (CSV). *J AI-Powered Med Innov.* 2024. DOI: 10.60087/japmi.vol01.issue01.p92
- [223] Paulick MG, et al. Promoting Sustainability through Next-Generation Biologics Drug Development. *Sustainability.* 2022. DOI: 10.3390/su14084401
- [224] Paulick MG, et al. Promoting Sustainability through Next-Generation Biologics Drug Development. *Sustainability.* 2022. DOI: 10.3390/su14084401
- [225] Nair A. Explainable AI in Gxp Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. *Clin Med Health Res J.* 2025. DOI: 10.18535/cmhrj.v5i05.509
- [226] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378
- [227] Nair A. Explainable AI in Gxp Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. *Clin Med Health Res J.* 2025. DOI: 10.18535/cmhrj.v5i05.509
- [228] Alves M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. *Crit Rev Anal Chem.* 2025. DOI: 10.1080/10408347.2025.2575352

- [229] Nair A. Explainable AI in Gxp Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. Clin Med Health Res J. 2025. DOI: 10.18535/cmhrj.v5i05.509
- [230] Singh AK, et al. Current trends in chromatographic prediction using artificial intelligence and machine learning. Anal Methods. 2023. DOI: 10.1039/d3ay00362k
- [231] Xu Z, et al. Retention time prediction for chromatographic enantioseparation by quantile geometry-enhanced graph neural network. Nat Commun. 2022. DOI: 10.1038/s41467-023-38853-3
- [232] Xu Z, et al. Retention time prediction for chromatographic enantioseparation by quantile geometry-enhanced graph neural network. Nat Commun. 2022. DOI: 10.1038/s41467-023-38853-3
- [233] Nair A. Explainable AI in Gxp Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. Clin Med Health Res J. 2025. DOI: 10.18535/cmhrj.v5i05.509
- [234] Nair A. Explainable AI in Gxp Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. Clin Med Health Res J. 2025. DOI: 10.18535/cmhrj.v5i05.509
- [235] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Sys-tems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [236] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technolog-ical Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378.v1
- [237] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Sys-tems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [238] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Sys-tems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [239] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technolog-ical Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378.v1
- [240] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Techno-logical Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378
- [241] Weller HN, et al. High Throughput Analysis and Purification in Support of Automated Parallel Synthesis. Mol Divers. 1997. DOI: 10.1023/A:1009636725336
- [242] Poonam. Pharmaceutical analysis techniques. Pharma Innov. 2019. DOI: 10.22271/tpi.2019.v8.i1m.25480
- [243] Gusev F, et al. Machine Learning anomaly detection of automated HPLC experiments in the Cloud Laboratory. 2025. DOI: 10.26434/chemrxiv-2025-7ggzl
- [244] Gusev F, et al. Machine Learning anomaly detection of automated HPLC experiments in the Cloud Laboratory. 2025. DOI: 10.26434/chemrxiv-2025-7ggzl
- [245] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Sys-tems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [246] Gusev F, et al. Machine Learning anomaly detection of automated HPLC experiments in the Cloud Laboratory. 2025. DOI: 10.26434/chemrxiv-2025-7ggzl
- [247] Gusev F, et al. Machine Learning anomaly detection of automated HPLC experiments in the Cloud Laboratory. 2025. DOI: 10.26434/chemrxiv-2025-7ggzl
- [248] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Sys-tems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [249] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technolog-ical Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378.v1
- [250] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Techno-logical Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378
- [251] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Sys-tems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [252] Gusev F, et al. Machine Learning anomaly detection of automated HPLC experiments in the Cloud Laboratory. 2025. DOI: 10.26434/chemrxiv-2025-7ggzl
- [253] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technolog-ical Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378.v1
- [254] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Techno-logical Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378
- [255] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Sys-tems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [256] Auclair S, et al. Biopharmaceutical Characterization in the Age of Artificial Intelligence. LCGC Int. 2025. DOI: 10.56530/lcgc.int.mv4086z4
- [257] Auclair S, et al. Biopharmaceutical Characterization in the Age of Artificial Intelligence.

- LCGC Int. 2025. DOI: 10.56530/lcgc.int.mv4086z4
- [258] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Systems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [259] Automated Real-Time Gradient Optimization and Predictive Maintenance for Reversed-Phase HPLC using Deep Reinforcement Learning. 2025. DOI: 10.5281/zenodo.16920185
- [260] Automated Real-Time Gradient Optimization and Predictive Maintenance for Reversed-Phase HPLC using Deep Reinforcement Learning. 2025. DOI: 10.5281/zenodo.16920184
- [261] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Systems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [262] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Systems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [263] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Systems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [264] El-Sayed GM, et al. DoE-enhanced development and validation of eco-friendly RP-HPLC method for analysis of safinamide and its precursor impurity: QbD approach. Microchem J. 2023. DOI: 10.1016/j.microc.2023.108730
- [265] Alves M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. Crit Rev Anal Chem. 2025. DOI: 10.1080/10408347.2025.2575352
- [266] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378.v1
- [267] Alves M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. Crit Rev Anal Chem. 2025. DOI: 10.1080/10408347.2025.2575352
- [268] M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. 2025. DOI: 10.6084/m9.figshare.30464378
- [269] Nair A. Explainable AI in Gxp Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. Clin Med Health Res J. 2025. DOI: 10.18535/cmhrj.v5i05.509
- [270] Alves M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. Crit Rev Anal Chem. 2025. DOI: 10.1080/10408347.2025.2575352
- [271] Alves M, et al. Artificial Intelligence in HPLC Method Development: A Critical Review of Technological Integration, Limitations, and Future Directions. Crit Rev Anal Chem. 2025. DOI: 10.1080/10408347.2025.2575352
- [272] Yang Q, et al. Prediction of Liquid Chromatographic Retention Time with Graph Neural Networks to Assist in Small Molecule Identification. Anal Chem. 2021. DOI: 10.1021/ACS.ANALCHEM.0C04071
- [273] Niazi SK. Regulatory Perspectives for AI/ML Implementation in Pharmaceutical GMP Environments. Pharmaceuticals. 2025. DOI: 10.3390/ph18060901
- [274] Ajmal M, et al. Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-Making. AAPS J. 2025. DOI: 10.1208/s12248-024-01006-5
- [275] Niazi SK. Regulatory Perspectives for AI/ML Implementation in Pharmaceutical GMP Environments. Pharmaceuticals. 2025. DOI: 10.3390/ph18060901
- [276] Ju R, et al. Deep Neural Network Pretrained by Weighted Autoencoders and Transfer Learning for Retention Time Prediction of Small Molecules. Anal Chem. 2021. DOI: 10.1021/ACS.ANALCHEM.1C03250
- [277] Ju R, et al. Deep Neural Network Pretrained by Weighted Autoencoders and Transfer Learning for Retention Time Prediction of Small Molecules. Anal Chem. 2021. DOI: 10.1021/ACS.ANALCHEM.1C03250
- [278] Gusev F, et al. Machine Learning anomaly detection of automated HPLC experiments in the Cloud Laboratory. 2025. DOI: 10.26434/chemrxiv-2025-7ggzl
- [279] Zaretskii M, et al. 3D chemical structures allow robust deep learning models for retention time prediction. Digit Discov. 2022. DOI: 10.1039/d2dd00021k
- [280] Ajmal M, et al. Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-Making. AAPS J. 2025. DOI: 10.1208/s12248-024-01006-5

- [281] Bhavanam R. Green, Portable and Smart HPLC: Sustainable Workflows, Miniaturised Systems and AI-Driven Chromatography. 2025. DOI: 10.61096/shareme.v4.iss4.2025.133-141
- [282] Bhavanam. HPLC in the Era of Biopharma: Advances in Column Chemistry, Automation and Data Analytics.
- [283] Ajmal M, et al. Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-Making. AAPS J. 2025. DOI: 10.1208/s12248-024-01006-5